| Combination of | |
|---|---|
| Trandolapril | Calcium channel blocker |
| Verapamil | ACE inhibitor |
| Clinical data | |
| Trade names | Tarka |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Trandolapril/verapamil (Tarka) [2] is an oral antihypertensive medication that combines a slow release formulation of verapamil hydrochloride, a calcium channel blocker, and an immediate release formulation of trandolapril, an ACE inhibitor. The patent, held by Abbott Laboratories, expired on February 24, 2015.
This combination medication contains angiotensin-converting enzyme (ACE) inhibitor and calcium channel blocker and is prescribed for high blood pressure. [3] [4] [5]
- ^ "Active substance(s): trandolapril / verapamil" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 29 October 2020.
- ^ "Tarka". drugs.com.
- ^ Reynolds NA, Wagstaff AJ, Keam SJ (2005). "Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension". Drugs. 65 (13): 1893–1914. doi: 10.2165/00003495-200565130-00011. PMID 16114984. S2CID 46962760.
- ^ García Donaire JA, Ruilope LM (2007). "Trandolapril/verapamil combination in hypertensive diabetic patients". Vascular Health and Risk Management. 3 (1): 77–82. PMC 1994049. PMID 17583177.
- ^ Sharma SK, Ruggenenti P, Remuzzi G (2007). "Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination". Vascular Health and Risk Management. 3 (4): 453–465. PMC 2291330. PMID 17969376.
- "Trandolapril mixture with verapamil hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
 | This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
| Combination of | |
|---|---|
| Trandolapril | Calcium channel blocker |
| Verapamil | ACE inhibitor |
| Clinical data | |
| Trade names | Tarka |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Trandolapril/verapamil (Tarka) [2] is an oral antihypertensive medication that combines a slow release formulation of verapamil hydrochloride, a calcium channel blocker, and an immediate release formulation of trandolapril, an ACE inhibitor. The patent, held by Abbott Laboratories, expired on February 24, 2015.
This combination medication contains angiotensin-converting enzyme (ACE) inhibitor and calcium channel blocker and is prescribed for high blood pressure. [3] [4] [5]
- ^ "Active substance(s): trandolapril / verapamil" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 29 October 2020.
- ^ "Tarka". drugs.com.
- ^ Reynolds NA, Wagstaff AJ, Keam SJ (2005). "Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension". Drugs. 65 (13): 1893–1914. doi: 10.2165/00003495-200565130-00011. PMID 16114984. S2CID 46962760.
- ^ García Donaire JA, Ruilope LM (2007). "Trandolapril/verapamil combination in hypertensive diabetic patients". Vascular Health and Risk Management. 3 (1): 77–82. PMC 1994049. PMID 17583177.
- ^ Sharma SK, Ruggenenti P, Remuzzi G (2007). "Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination". Vascular Health and Risk Management. 3 (4): 453–465. PMC 2291330. PMID 17969376.
- "Trandolapril mixture with verapamil hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
|
| This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |